HUP0303136A2 - Iloperidon új felhasználási módja és ezt tartalmazó gyógyszerkészítmény - Google Patents

Iloperidon új felhasználási módja és ezt tartalmazó gyógyszerkészítmény

Info

Publication number
HUP0303136A2
HUP0303136A2 HU0303136A HUP0303136A HUP0303136A2 HU P0303136 A2 HUP0303136 A2 HU P0303136A2 HU 0303136 A HU0303136 A HU 0303136A HU P0303136 A HUP0303136 A HU P0303136A HU P0303136 A2 HUP0303136 A2 HU P0303136A2
Authority
HU
Hungary
Prior art keywords
iloperidone
subject
emotional
treatment
pharmaceutically acceptable
Prior art date
Application number
HU0303136A
Other languages
English (en)
Inventor
Hans O. Kalkman
Original Assignee
Novartis Ag.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag. filed Critical Novartis Ag.
Publication of HUP0303136A2 publication Critical patent/HUP0303136A2/hu
Publication of HUP0303136A3 publication Critical patent/HUP0303136A3/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4515—Non condensed piperidines, e.g. piperocaine having a butyrophenone group in position 1, e.g. haloperidol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Organic Chemistry (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

A találmány tárgya iloperidon felhasználása emóciós betegségek,egyebek között a bipoláros hangulatváltozások, kezelésére. Közelebbrőla találmány tárgya az 1-[4-[3-[4-(6-fluor-1,2-benzizoxazol-3-il)-1-piperidinil]-propoxi]-3-metoxi-fenil]-etanon vagy gyógyászatilagelfogadható savaddíciós sói emóciós és/vagy figyelemösszpontosításivagy viselkedési rendellenességek gyógyítására való alkalmazásra. Atalálmány tárgya továbbá emóciós és/vagy figyelemösszpontosítási vagyviselkedési rendellenességek kezelésére alkalmas gyógyszerkészítmény,amely 1-[4-[3-[4-(6-fluor-1,2-benzizoxazol-3-il)-1-piperidinil]-propoxi]-3-metoxi-fenil]-etanont vagy annak valamely gyógyászatilagelfogadható savaddíciós sóját legalább egy gyógyászatilag elfogadhatóvivőanyaggal együtt tartalmazza. Ó
HU0303136A 2001-02-05 2002-02-04 New use of iloperidone and pharmaceutical composition containing it HUP0303136A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0102841.4A GB0102841D0 (en) 2001-02-05 2001-02-05 Organic compounds
PCT/EP2002/001130 WO2002064141A1 (en) 2001-02-05 2002-02-04 New use of iloperidone

Publications (2)

Publication Number Publication Date
HUP0303136A2 true HUP0303136A2 (hu) 2003-12-29
HUP0303136A3 HUP0303136A3 (en) 2006-05-29

Family

ID=9908143

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0303136A HUP0303136A3 (en) 2001-02-05 2002-02-04 New use of iloperidone and pharmaceutical composition containing it

Country Status (21)

Country Link
US (4) US20040072869A1 (hu)
EP (1) EP1370262A1 (hu)
JP (1) JP4278981B2 (hu)
KR (1) KR100851256B1 (hu)
CN (1) CN1226035C (hu)
AU (1) AU2002231766B2 (hu)
BR (1) BR0206918A (hu)
CA (1) CA2434900C (hu)
CZ (1) CZ301357B6 (hu)
GB (1) GB0102841D0 (hu)
HU (1) HUP0303136A3 (hu)
IL (3) IL156819A0 (hu)
MX (1) MXPA03006970A (hu)
NO (1) NO20033163L (hu)
NZ (1) NZ527111A (hu)
PL (1) PL362550A1 (hu)
RU (1) RU2301065C2 (hu)
SK (1) SK9812003A3 (hu)
TW (1) TWI322011B (hu)
WO (1) WO2002064141A1 (hu)
ZA (1) ZA200305331B (hu)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2005292246B2 (en) 2004-09-30 2011-07-07 Vanda Pharmaceuticals, Inc Methods for the administration of iloperidone
US20100063093A1 (en) 2007-03-28 2010-03-11 Curt Wolfgang Methods for the administration of iloperidone
RU2008150624A (ru) * 2006-05-22 2010-06-27 Ванда Фармасьютиклз, Инк. (Us) Лечение депрессивных расстройств
CN101822673B (zh) * 2009-03-04 2013-09-18 北京德众万全药物技术开发有限公司 一种含有伊潘立酮的固体药物组合物

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE126512T1 (de) * 1989-05-19 1995-09-15 Hoechst Roussel Pharma N-(aryloxyalkyl)heteroarylpiperidine und - heteroarylpiperazine, verfahren zu ihrer herstellung und ihre verwendung als medikamente.
FR2654104B1 (fr) * 1989-11-07 1992-01-03 Adir Nouveaux derives du 1,2-benzisoxazole, leurs procedes de preparation et les compositions pharmaceutiques qui les contiennent.
CA2300148C (en) * 1997-08-11 2009-06-23 University Of South Florida Nicotine antagonists for nicotine-responsive neuropsychiatric disorders
US5955459A (en) * 1997-11-26 1999-09-21 Neuromedica, Inc. Fatty acid-antipsychotic compositions and uses thereof
KR20010072878A (ko) * 1998-10-16 2001-07-31 디르크 반테 인식을 개선하기 위한 아세틸콜린에스테라제 억제제와배합된 비정형 항정신병제
EP1242058A1 (en) * 1999-04-07 2002-09-25 Pfizer Products Inc. Use of cyp2d6 inhibitors in combination therapies

Also Published As

Publication number Publication date
US20090131477A1 (en) 2009-05-21
NZ527111A (en) 2005-05-27
CZ20032114A3 (cs) 2004-01-14
EP1370262A1 (en) 2003-12-17
JP2004517959A (ja) 2004-06-17
IL156819A0 (en) 2004-02-08
NO20033163D0 (no) 2003-07-10
IL156819A (en) 2008-03-20
RU2003126175A (ru) 2005-03-10
CN1226035C (zh) 2005-11-09
SK9812003A3 (en) 2004-04-06
AU2002231766B2 (en) 2005-12-22
US20040072869A1 (en) 2004-04-15
WO2002064141A1 (en) 2002-08-22
TWI322011B (en) 2010-03-21
CA2434900C (en) 2010-10-05
ZA200305331B (en) 2004-05-12
HUP0303136A3 (en) 2006-05-29
CA2434900A1 (en) 2002-08-22
CZ301357B6 (cs) 2010-01-27
NO20033163L (no) 2003-07-10
CN1531432A (zh) 2004-09-22
US20060205786A1 (en) 2006-09-14
MXPA03006970A (es) 2003-11-18
PL362550A1 (en) 2004-11-02
IL188485A0 (en) 2008-03-20
GB0102841D0 (en) 2001-03-21
US20080103177A1 (en) 2008-05-01
BR0206918A (pt) 2004-02-03
RU2301065C2 (ru) 2007-06-20
KR20030070599A (ko) 2003-08-30
KR100851256B1 (ko) 2008-08-08
JP4278981B2 (ja) 2009-06-17

Similar Documents

Publication Publication Date Title
Kolte et al. Assessment of gingival thickness with regards to age, gender and arch location
Vissink et al. The medically compromised patient: Are dental implants a feasible option?
US20220088021A1 (en) Methods of diagnosing and treating cancer
Esper et al. The role of keratinized mucosa in peri-implant health
CY1107369T1 (el) Μεθοδος για την παραγωγη μιας στερεας, χορηγουμενης απο του στοματος φαρμακευτικης συνθεσης με 5-χλωρο-ν({(5s)-2-οξο-3-[4-(3-οξο-4-μορφολινυλο)-φαινυλο]-1,3-οξαζολιδιν-5-υλο}-μεθυλο)-2-θειοφαινο-καρβοξαμιδιο
Brunton et al. Procera all-ceramic crowns: a new approach to an old problem?
HUP0301512A2 (hu) Gyomor-bél csatornában fellépő kötőszöveti váz tumorok kezelése
DeBowes et al. Parkinson’s disease: considerations for dental hygienists
Zeppetella Evidence-based treatment of cancer-related breakthrough pain with opioids
Arnhart et al. Impact of implant surface topography: a clinical study with a mean functional loading time of 85 months
MA28240A1 (fr) Combinaison de (a) { n-5-[4-(4-methyl-piperazino-methyl)-benzoylamido]-2-methylphenyl-4-(3-pyridyl)-2-pyrimidine-amine et (b) au moins un inhibiteur de formation de l'hypusine et son utilisation
Oh et al. Optimization of maxillary obturator thickness using a double‐processing technique
HUP0303136A2 (hu) Iloperidon új felhasználási módja és ezt tartalmazó gyógyszerkészítmény
HUP0204050A2 (hu) Mirtazapint és gepiront tartalmazó hatóanyagkombináció depresszió és rokon rendellenességek kezelésére
Ghanem et al. Dimensional accuracy of different techniques used for complete‐arch multi‐implant impressions
JP2009501744A5 (hu)
HN2005000210A (es) Composicion farmaceutica antimicobacteriana que comprende un farmaco antituberculoso.
RU2007147957A (ru) Комбинация производных пиримидиламинобензамида и иматиниба для лечения или профилактики пролиферативных заболеваний
RU2008125858A (ru) Производные пиразолоизохинолина
YU88103A (sh) Lecenje adhd
Miremadi et al. A randomized controlled trial comparing surgical and non‐surgical periodontal therapy: a 3‐year clinical and cost‐effectiveness analysis
AU2003232805A1 (en) Pharmaceutical active substance combination and the use thereof
AR045330A1 (es) Forma de dosificacion oral, procedimiento para su preparacion y uso del compuesto 5-(4-(2-(n-metil-n- (2-piridil)amino)etoxi )bencil) tiazolidin-2,4-diona o una sal o solvato farmaceuticamente aceptable del mismo para prepararla
Pathak et al. Periodontal parameters around implants and natural teeth
Gadhavi et al. A survey on the use of various gingival displacement techniques in fixed partial denture by the prosthodontists in vadodara city

Legal Events

Date Code Title Description
FD9A Lapse of provisional protection due to non-payment of fees